Pancreatic Adenocarcinoma

  • Paul B. Romesser
  • Michael R. Folkert
  • Karyn A. GoodmanEmail author
Part of the Medical Radiology book series (MEDRAD)


The pancreas, a retroperitoneal organ that performs a range of both endocrine and exocrine functions, lies within the curve of the first, second, and third parts of the duodenum (i.e., the C loop) and extends across the posterior abdominal wall behind the stomach to the splenic hilum. It is divided into four parts (head, neck, body, and tail) and one accessory lobe, the uncinate process (Fig. 1) (Strandring 2005).


  1. Berger AC, Garcia M Jr, Hoffman JP et al (2008) Postresection CA 19–9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26:5918–5922CrossRefGoogle Scholar
  2. Callery MP, Chang KJ, Fishman EK et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733CrossRefGoogle Scholar
  3. Dholakia AS, Chang DT, Goodman KA et al (2013) A phase II multi-center study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for locally advanced pancreatic adenocarcinoma. Accepted for oral presentation at the ASTRO annual meeting, Atlanta, GA.Google Scholar
  4. Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, ChicagoGoogle Scholar
  5. Goodman KA, Regine WF, Dawson LA et al (2012) Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys 83:901–908CrossRefGoogle Scholar
  6. Iacobuzio-Donahue CA, Fu B, Yachida S et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806–1813CrossRefGoogle Scholar
  7. Murphy JD, Christman-Skieller C, Kim J et al (2010) A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 78:1420–1426CrossRefGoogle Scholar
  8. National Comprehensive Cancer (NCC) Network (2013) NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Verison 1.2013Google Scholar
  9. Niederhuber JE, Armitage JO, Doroshow JH et al (eds) (2014) Abeloff’s clinical oncology. Elsevier/Churchill Livingstone, PhiladelphiaGoogle Scholar
  10. Schellenberg D, Quon A, Minn AY et al (2010) 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 77:1420–1425CrossRefGoogle Scholar
  11. Strandring S (ed) (2005) Gray’s anatomy: the anatomical basis of clinical practice, 39th edn. Elsevier/Churchill Livingstone, New YorkGoogle Scholar
  12. Yovino S, Poppe M, Jabbour S et al (2011) Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 79:158–162CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Paul B. Romesser
    • 1
  • Michael R. Folkert
    • 1
  • Karyn A. Goodman
    • 1
    Email author
  1. 1.Department of Radiation OncologyMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations